The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I too hold both.
The thing that's knocked my confidence in PACB was their Apto bioscience purchase and the $100m dilution to us in order to purchase.
$100m in this current high interest rate environment for a company with no tangible product is insane. Paid way too much. $85m upfront is too much. Should have been $50m or less upfront and then strict milestones with conservative milestones, in order to trigger the final $50m (still too much).
As well, don't forget that there was approx $100m dilution from the Omniome purchase. at the beginning of October. We don't even know how stellar the Onso product sales will be . They have to be pressed to provide a backlog number and a GM.
LLL -
ASML - largest holding came out with this today
"AMSTERDAM, Oct 18 (Reuters) - Semiconductor equipment maker ASML Holding NV (ASML.AS) reported lower-than-expected orders on Wednesday and warned of flat sales next year as customers conserve cash against an uncertain economic backdrop, hitting its shares.
Europe's largest technology firm said the semiconductor industry was probably near a trough but that "customers continue to be uncertain about the shape of the demand recovery ... we therefore expect 2024 to be a transition year"."
Was 4% down in the morning, now recovered to 2.6% down
I wonder if they'll dish the treasury shares out to the 'worthy' fund managers whom have done an excellent job this last 12m as evidenced by the stock - NAV discount?
------------------------------------------------
On 12 October 2023 the Company purchased 150,000 ordinary shares at a price of 692.2670p. The shares purchased will be held in Treasury.
Following the transaction the Company holds 79,450,978 shares in Treasury.
The shares in issue less the total number of shares in Treasury are 1,405,329,902.
Dorset,
MRNA are doing great things and actually their pipeline is promising and things are looking up.
Unfortunately, its valuation was and is based on COVID revs which keep declining. Even when shots are available to buy, people won't buy them. What's the uptake of the flu vaccine. Pretty poor unless you're over 65.
Their other vaccines make more sense (but their rev estimates will probably be too optimistic, since they'll be negotiated down on price)
25p isn't bad actually . Still sitting on a profit, Compared to my 95p cost basis for tlw!
I think I'll channel some dividend income into HBR next and see if I can tank that stock too. My cost basis for that is north of 2000p.
RBC cuts Morgan Advanced Materials price target to 330 (370) pence - 'outperform'
Not shorting...just reiterating that TLW never ceases to surprise on the downside.
Oil has been moving up nicely before this week, yet TLW didn't seem to follow.
Same goes for HBR.
Oil services stocks have been hammered this week. DVN is looking a nice bargain + variable dividend.
(Scrodingerscat - have you trimmed your position over time?)
OMG! Last time I checked, this was knocking on the door of 39p.!
Good ol' TLW. Never ceases to surprise on the upside. These PT's are going lower because they look stupid. Even 55p in 12m is a pipedream. Probably would have gone to 40p, but felt sorry for TLW.
Brent is at $90 and WTI at $88.5, and this sorry stock is falling.
Market seriously doesn't have faith in its ability to profit from its licenses to boost cash pile and lower debt. Political situation in Gabon has put work by TLW on the back burner (despite the extension). Why invest and drilled if you could be ousted once oil flows?
As for Kenya....my oh my! This time next year, no progress or the license will be handed back (sold).
As for next-generation genomic sequencing, Bernstein said it’s bullish on Pacific Biosciences (NASDAQ:PACB) but bearish on sub-sector giant Illumina (NASDAQ:ILMN), due in part to a shift from short-read sequencing by synthesis, or SBS, which Illumina dominates, to a “more competitive landscape” that includes technologies such as long-read sequencing.
In the case of Illumina, Bernstein asserted that its “monopoly” was under attack, making it the relative “loser” in the space. Bernstein rated Illumina at underperform, despite a “huge collapse” of its share price. “We think there is further downside,” Bernstein added, setting Illumina’s price target at $111.
Meanwhile, Bernstein said it viewed PacBio as the relative “winner,” stating that PacBio’s pipeline was set up to grab market share in both the long and short-read categories. “PacBio is at a huge point of inflection in growth,” the investment firm added. Bernstein rated PacBio outperform, with a price target of $11.